Author:
Robbins Laurel,Balaram Ariane,Dejneka Stefanie,McMahon Matthew,Najibi Zarina,Pawlowicz Peter,Conrad William H.
Abstract
AbstractTuberculosis (TB) is the second leading cause of death by a single infectious disease behind COVID-19. Despite a century of effort, the current TB vaccine does not effectively prevent pulmonary TB, promote herd immunity, or prevent transmission. Therefore, alternative approaches are needed. We seek to develop a cell therapy that produces an effective antibiotic in response to TB infection. D-cycloserine (D-CS) is a second-line antibiotic for TB that inhibits bacterial cell wall synthesis. We have determined D-CS to be the optimal candidate for anti-TB cell therapy due to its effectiveness against TB, relatively short biosynthetic pathway, and its low-resistance incidence. The first committed step towards D-CS synthesis is catalyzed by the L-serine-O-acetyltransferase (DcsE) which converts L-serine and acetyl-CoA to O-acetyl-L-serine (L-OAS). To test if the D-CS pathway could be an effective prophylaxis for TB, we endeavored to express functional DcsE in A549 cells as a human pulmonary model. We observed DcsE-FLAG-GFP expression using fluorescence microscopy. DcsE purified from A549 cells catalyzed the synthesis of L-OAS as observed by HPLC–MS. Therefore, human cells synthesize functional DcsE capable of converting L-serine and acetyl-CoA to L-OAS demonstrating the first step towards D-CS production in human cells.
Publisher
Springer Science and Business Media LLC
Reference105 articles.
1. Koch, R. The etiology of tuberculosis. Berl. Klin. Wocbenschift 10, 221–230 (1882).
2. World Health Organization. Global tuberculosis report 2021. https://www.who.int/publications-detail-redirect/9789240037021 (2021).
3. Principi, N. & Esposito, S. The present and future of tuberculosis vaccinations. Tuberculosis 95, 6–13 (2015).
4. Tameris, M. et al. The candidate TB vaccine, MVA85A, induces highly durable Th1 responses. PLoS ONE 9, e87340 (2014).
5. Smieja, M., Marchetti, C., Cook, D. & Smaill, F. M. Isoniazid for preventing tuberculosis in non‐HIV infected persons. Cochrane Database Syst. Rev. 1999, CD001363 (1999).